Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 1Brain Neoplasms 1

Interventions

pembrolizumab 2Specimen Handling 2Propranolol 2talimogene laherparepvec 1sargramostim 1romiplostim 1propranolol CR 1imisopasem manganese 1gusacitinib 1dabrafenib 1cobimetinib 1cemiplimab 1aldesleukin 1Vemurafenib 1Vaccines 1Surgical Procedures, Operative 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Practice Guidelines as Topic 1Paclitaxel 1Nivolumab 1Nanoparticles 1Microscopy, Confocal 1Magnetic Resonance Spectroscopy 1Ketones 1Interleukin-2 1Glucose 1Drug Therapy 1Diet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × CA-4948 × Dermatologic × Clear all
NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

University of Florida

Phase 1/2 Suspended
29 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡